Silibinin: A thorny therapeutic for EGF-R expressing tumors?

Cancer Biology and Therapy

Volumn 2, Issue 5, 2003, Pages 532-533

  Hannay, Jonathan A F ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

EGF receptor; Milk thistle; Silibinin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SILIBININ; SILYMARIN;

ANIMAL; BRAIN TUMOR; CELL SURVIVAL; DRUG EFFECT; GLIOMA; HUMAN; METABOLISM; NOTE; PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SILYBUM MARIANUM;

ANIMALS; BRAIN NEOPLASMS; CELL SURVIVAL; GLIOMA; HUMANS; MILK THISTLE; PHOSPHORYLATION; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SILYMARIN;

EID: 1542787635     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.5.536     Document Type: Note

References (12)

1. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998; 93:139-43. (Pubitemid 29063954)
2. Singh RP, Tyagi AK, Zhao J, Agarwal R. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis. 2002; 23:499-510. (Pubitemid 34257631)
3. Zi X, Grasso AW, Kung HJ, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res. 1998; 58:1920-9. (Pubitemid 28217468)
4. Tyagi A, Agarwal C, Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgendependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol Cancer Ther. 2002; 1:525-32.
5. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis.Oncogene. 2002; 21:1759-67.
6. Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis. 2001; 22:1399-403. (Pubitemid 32898696)
7. Zi X, Zhang J, Agarwal R, Pollack M. Silibinin up-regulates insulin-like growth factorbinding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res. 2000; 60:5617-20.
8. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci U S A. 1999; 96:7490-5. (Pubitemid 29299689)
9. Zi X, Agarwal R. Modulation of mitogen-activated protein kinases activation Biochem Biophys Res Commun. 1999; 263:528-36.
10. Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002; 8:3512-9.
11. Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer. 2003;106:699-705. (Pubitemid 36993393)
12. Qi L, Singh RP, Lu Y, Agarwal R, Harrison GS, Franzusoff A, Glodé LM. Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Bio Ther 2003; 2:526-31.